“一年两针”，诺华降脂疗法新适应症在中国申报上市
国家药监局药品审评中心（CDE）官网最新公示，诺华（Novartis）申报的英克司兰钠注射液新适应症上市申请获得受理。
媒体报道
新适应症！诺华 first in class 新药在国内报上市 医药魔方
“一年两针”，诺华降脂疗法新适应症在中国申报上市 钛媒体
“一年两针” 诺华降脂疗法新适应症在中国申报上市 财联社
事件追踪
2025-03-04 诺华放射性癌症疗法1类新药在中国获批临床
#热门话题
BY Readhub
However, analysts are positive on the stock now. “We have seen a huge downside movement in the stock due to the central electricity regulatory commission’s (CERC) order that seems to be negative from 2014-15 onwards but we cannot take a linear negative view on the stock and further downside movement on the stock is unlikely. Currently stock is underpriced. Investors can bet on it for a longer horizon," said Vivek Gupta, director research at CapitalVia Global Research.
Telegram is riding high, adding tens of million of users this year. Now the bill is coming due.Telegram is one of the few significant social-media challengers to Facebook Inc., FB -1.90% on a trajectory toward one billion users active each month by the end of 2022, up from roughly 550 million today.
Readhub from us